PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19409865-4 2009 This degradation was effectively prevented by pre-treatment with neostigmine (100 microg) in the sampling tube, but not by EDTA pre-treatment, indicating that landiolol could be metabolized by pseudocholinesterase in plasma. Neostigmine 65-76 butyrylcholinesterase Homo sapiens 193-213 17950687-1 2008 The inhibition of horse serum butyrylcholinesterase (EC 3.1.1.8) by three carbamates (eserine, neostigmine, and rivastigmine) was studied by flow microcalorimetry at 37 degrees C in Tris buffer (pH 7.5). Neostigmine 95-106 butyrylcholinesterase Homo sapiens 30-51 19138245-1 2008 BACKGROUND: As spinal cholinergic receptors participate in the control of somatic pain, this effect could be potentiated by intrathecal injection of a cholinesterase inhibitor, neostigmine. Neostigmine 177-188 butyrylcholinesterase Homo sapiens 151-165 17122235-1 2006 We previously demonstrated the effectiveness of epidural sufentanil and the cholinesterase inhibitor, neostigmine, to initiate selective labor analgesia. Neostigmine 102-113 butyrylcholinesterase Homo sapiens 76-90 11521162-10 2001 Inhibitors of cholinesterase (physostigmine, neostigmine; 3 microM) facilitated the efflux of acetylcholine about sixfold, and a combination of both (+)-tubocurarine (30 microM) and scopolamine (1 microM) halved the enhancing effect. Neostigmine 45-56 butyrylcholinesterase Homo sapiens 14-28 15915024-10 2005 Neostigmine injected after cholinesterase shortened recovery further, and a train-of-four ratio of 0.8 was reached in 10-30 min. Neostigmine 0-11 butyrylcholinesterase Homo sapiens 27-41 15915024-13 2005 Injection of neostigmine after the administration of cholinesterase speeds up recovery. Neostigmine 13-24 butyrylcholinesterase Homo sapiens 53-67 15896593-0 2005 Neostigmine-induced prolonged neuromuscular blockade in a patient with atypical pseudocholinesterase. Neostigmine 0-11 butyrylcholinesterase Homo sapiens 80-100 12712872-4 2003 Such an effect, which has been described for cholinesterase inhibitors like neostigmine and donepezil, would explain the prolonged effect of succinylcholine. Neostigmine 76-87 butyrylcholinesterase Homo sapiens 45-59 12073883-1 2002 An enzyme inhibition biosensor, developed in our laboratory and previously used for the analysis of compounds with anticholinesterase activity (e.g. physostigmine, neostigmine, pyridostigmine nicotine and organophosphorus compounds) has now been tested for the analysis of another recently synthesized cholinesterase inhibitor, i.e. eptastigmine. Neostigmine 164-175 butyrylcholinesterase Homo sapiens 119-133 11668032-1 2001 The cholinesterase inhibitor neostigmine indirectly stimulates muscarinic M(1)/M(2)/M(3) receptors, thereby reducing colonic distension in acute colonic pseudo-obstruction. Neostigmine 29-40 butyrylcholinesterase Homo sapiens 4-18 12242967-7 2002 For 3 months, the infant was treated with neostigmin (cholinesterase inhibitor). Neostigmine 42-52 butyrylcholinesterase Homo sapiens 54-68 10069522-6 1999 Although no cholinergic agonists have been tested for safety in humans, the cholinesterase inhibitor, neostigmine, has undergone such testing, and produces analgesia to experimental, acute postoperative, and chronic pain. Neostigmine 102-113 butyrylcholinesterase Homo sapiens 76-90 10094138-1 1999 The effect of the cholinesterase inhibitor neostigmine on hippocampal noradrenaline (NA) release was studied using in vivo microdialysis. Neostigmine 43-54 butyrylcholinesterase Homo sapiens 18-32 10094138-7 1999 The fact that neostigmine is able to enhance both cholinergic and noradrenergic neurotransmission may help to understand the beneficial effect of cholinesterase inhibitors in Alzheimer"s disease. Neostigmine 14-25 butyrylcholinesterase Homo sapiens 146-160 9806710-0 1998 The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity. Neostigmine 29-40 butyrylcholinesterase Homo sapiens 67-87 8955970-6 1996 The plasma cholinesterase activity (PCHE) after neostigmine decreased from 6596 to 1959 U.L-1 (P < 0.001) but there was no change after edrophonium (6140 to 6396 U.L-1). Neostigmine 48-59 butyrylcholinesterase Homo sapiens 11-25 8863503-7 1996 The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine. Neostigmine 29-40 butyrylcholinesterase Homo sapiens 4-18 8863503-7 1996 The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine. Neostigmine 123-134 butyrylcholinesterase Homo sapiens 4-18 34994010-4 2022 Compound 2d showed the most potent inhibitory activity among the tested molecules toward AChE and BChE (IC50 = 15.07 and 14.15 nM) compared to the standard drug neostigmine. Neostigmine 162-173 butyrylcholinesterase Homo sapiens 98-102 1991816-2 1991 The aim of our study was to verify in two groups of children with idiopathic short stature the effect of intranasal administration of neostigmine (inNS; 3 mg), a cholinesterase inhibitor, on basal GH levels as well as on the somatotroph response to GHRH when the peptide was administered either iv (ivGHRH; 1 microgram/kg) or intranasally (inGHRH; 10 micrograms/kg). Neostigmine 134-145 butyrylcholinesterase Homo sapiens 162-176 8638849-15 1996 Bovine pseudocholinesterase and human plasma cholinesterase equally reversed the effects of succinylcholine but acetylcholinesterase did not, whereas the addition of 10 micrograms/ml neostigmine to the enzymes inhibited the reversal of succinylcholine. Neostigmine 183-194 butyrylcholinesterase Homo sapiens 13-27 7486038-9 1995 Plasma cholinesterase activity was decreased to 29% of control at 15 min and remained at approximately 60% of the control after neostigmine administration. Neostigmine 128-139 butyrylcholinesterase Homo sapiens 7-21 7605023-8 1995 Neostigmine decreased plasma cholinesterase activity and increased plasma concentrations of the trans-trans and cis-trans stereoisomers of mivacurium (P < 0.05). Neostigmine 0-11 butyrylcholinesterase Homo sapiens 29-43 8095014-1 1993 GH secretion is stimulated by the administration of cholinesterase inhibitors (such as pyridostigmine and neostigmine) in several species, including man. Neostigmine 106-117 butyrylcholinesterase Homo sapiens 52-66 1522952-2 1992 Injections of the cholinesterase inhibitor, neostigmine bromide, induced a stiff, tremulous state and lowered myoclonic, clonic and tonic seizure thresholds. Neostigmine 44-63 butyrylcholinesterase Homo sapiens 18-32 34540646-7 2021 Neostigmine is a cholinesterase inhibitor that exerts its effect by competitively binding at the active site of acetylcholinesterase, which prevents the hydrolysis of acetylcholine and subsequently retaining acetylcholine at the nerve terminal. Neostigmine 0-11 butyrylcholinesterase Homo sapiens 17-31 2459657-8 1988 The cholinesterase inhibitor neostigmine increased the amplitude and prolonged the time course of Schwann-cell mepc to a similar degree after short and long term denervation, which indicates that cholinesterase was still functional after 3-4 months of denervation. Neostigmine 29-40 butyrylcholinesterase Homo sapiens 4-18 2637954-0 1989 Effect of suxamethonium, pancuronium, neostigmine and halothane on serum cholinesterase activity. Neostigmine 38-49 butyrylcholinesterase Homo sapiens 73-87 2459657-8 1988 The cholinesterase inhibitor neostigmine increased the amplitude and prolonged the time course of Schwann-cell mepc to a similar degree after short and long term denervation, which indicates that cholinesterase was still functional after 3-4 months of denervation. Neostigmine 29-40 butyrylcholinesterase Homo sapiens 196-210 6610744-9 1984 Diethyldimethylpyrophosphonate , neostigmine, eserine, and di-isopropyl fluorophosphonate inhibited ChE activity in this order of potency. Neostigmine 33-44 butyrylcholinesterase Homo sapiens 100-103 3524957-1 1986 This review deals mainly with the pharmacokinetics of the reversible quaternary cholinesterase inhibitors neostigmine, pyridostigmine and edrophonium, which are mainly used to antagonise non-depolarising neuromuscular blockade in general anaesthesia and in the symptomatic treatment of myasthenia gravis. Neostigmine 106-117 butyrylcholinesterase Homo sapiens 80-94 3999598-7 1985 Local application of cholinesterase inhibitors in the form of Eserine, Prostigmin etc. Neostigmine 71-81 butyrylcholinesterase Homo sapiens 21-35 6610744-11 1984 Neostigmine, 0.15 and 0.4 microM, increased the time constant of miniature end-plate currents 1.3- and 1.8-fold, and slowed down ChE activity of muscle homogenates by 1.4 and 2.1 times, respectively, without significantly affecting ACh hydrolysis by intact muscles. Neostigmine 0-11 butyrylcholinesterase Homo sapiens 129-132 6284424-15 1982 These results suggest that at the frog neuromuscular junction the effects of neostigmine are explained primarily by its inhibition of cholinesterase, whereas physostigmine are explained primarily by its inhibition of cholinesterase, whereas physostigmine has an additional action on nerve terminals of decreasing nerve-stimulated release of acetylcholine. Neostigmine 77-88 butyrylcholinesterase Homo sapiens 134-148 6626182-7 1983 The residual labelling (8%) of band I but not band II (4%) was removed by preincubation of partially purified enzyme preparation with neostigmine (a selective inhibitor of cholinesterase). Neostigmine 134-145 butyrylcholinesterase Homo sapiens 172-186 7074413-0 1982 Effects of neostigmine and pyridostigmine on serum cholinesterase activity. Neostigmine 11-22 butyrylcholinesterase Homo sapiens 51-65 7055744-0 1982 Effects of neostigmine and pyridostigmine on serum cholinesterase activity. Neostigmine 11-22 butyrylcholinesterase Homo sapiens 51-65 7055744-1 1982 Serum cholinesterase activities were measured from 270 minutes in patients following administration of neostigmine or pyridostigmine for the reversal of pancuronium block in groups of seven patients each. Neostigmine 103-114 butyrylcholinesterase Homo sapiens 6-20 6257899-14 1980 Following inhibition of cholinesterase activity by neostigmine, similar effects on m.e.p.c.s and single channel properties were still observed on changing to 2 mM-Sr2+--Ringer. Neostigmine 51-62 butyrylcholinesterase Homo sapiens 24-38 7272149-0 1981 Effect of neostigmine and pyridostigmine on the plasma cholinesterase activity. Neostigmine 10-21 butyrylcholinesterase Homo sapiens 55-69 7272149-1 1981 The effect of neostigmine 0.05 mg kg-1 or pyridostigmine 0.25 mg kg-1 on serum cholinesterase activity was investigated in 20 adult patients undergoing elective surgery. Neostigmine 14-25 butyrylcholinesterase Homo sapiens 79-93 203742-7 1977 Of great significance in ocular myasthenia is the local application of cholinesterase inhibitors like Eserine, Prostigmin or Phospholine Iodide. Neostigmine 111-121 butyrylcholinesterase Homo sapiens 71-85 150548-4 1978 A trial of substitutive treatment was undertaken activating the cholinergic system with a precursor of acetylcholine (dimethyl-amino-ethanol-deanol--Bimanol) with simultaneous inhibition of cholinesterase with prostigmin. Neostigmine 210-220 butyrylcholinesterase Homo sapiens 190-204 1138751-0 1975 Potentiation of suxamethonium blockade by neostigmine in patients with atypical cholinesterase. Neostigmine 42-53 butyrylcholinesterase Homo sapiens 80-94 984487-0 1976 Serum cholinesterase activity following pancuronium and antagonism with neostigmine or pyridostigmine. Neostigmine 72-83 butyrylcholinesterase Homo sapiens 6-20 861116-3 1977 On the other hand, in patients with atypical plasma cholinesterase activity, neostigmine potentiated the depolarizing phase of suxamethonium block, while antagonizing the desensitizing phase. Neostigmine 77-88 butyrylcholinesterase Homo sapiens 52-66 13939168-0 1962 Hydrolysis of neostigmine by plasma cholinesterase. Neostigmine 14-25 butyrylcholinesterase Homo sapiens 36-50 4343315-2 1972 Studies involving the electrophoretic administration of antagonists of ACh (atropine, DHbetaE) and cholinesterase inhibitors (neostigmine, physostigmine) to MGN neurones indicate that ACh is an excitatory transmitter in the feline MGN, most probably released from fibres which originate in or traverse the mesencephalon.2. Neostigmine 126-137 butyrylcholinesterase Homo sapiens 99-113 5967132-0 1966 [Correlation of changes in the adrenocortical function and cholinesterase activity of the blood and brain under the influence of proserine]. Neostigmine 129-138 butyrylcholinesterase Homo sapiens 59-73 13956631-0 1962 [Changes of cardiac activity of myasthenic patients during the use of anti-cholinesterase preparations (oxazil and proserine)]. Neostigmine 115-124 butyrylcholinesterase Homo sapiens 75-89 13781449-0 1960 [Blood cholinesterase during the treatment of myasthenia by anti-cholinesterase drugs (prostigmine and mestinon)]. Neostigmine 87-98 butyrylcholinesterase Homo sapiens 7-21 13781449-0 1960 [Blood cholinesterase during the treatment of myasthenia by anti-cholinesterase drugs (prostigmine and mestinon)]. Neostigmine 87-98 butyrylcholinesterase Homo sapiens 65-79 13234044-0 1955 Inactivation of cholinesterase by compounds related to neostigmine. Neostigmine 55-66 butyrylcholinesterase Homo sapiens 16-30 14934691-0 1951 [Qualitative studies on the inhibition of the cholinesterase in erythrocytes by prostigmine and choline]. Neostigmine 80-91 butyrylcholinesterase Homo sapiens 46-60 5957441-0 1966 Serum cholinesterase in anaesthesia with reference to neostigmine, fentanyl, and dihydrobenzpiridol. Neostigmine 54-65 butyrylcholinesterase Homo sapiens 6-20 14331249-0 1965 [PROTECTION EXERCISED BY CHOLINESTERASE INHIBITORS WITH 1 OR 2 QUATERNARY AMMONIUM FUNCTIONS AGAINST THE INHIBITORY CAPACITY OF PROSTIGMINE]. Neostigmine 128-139 butyrylcholinesterase Homo sapiens 25-39 13823694-0 1960 Reactivation of neostigmine inhibited human plasma cholinesterase. Neostigmine 16-27 butyrylcholinesterase Homo sapiens 51-65 13062582-0 1953 [Atropine interference of prostigmine effect on human blood cholinesterase]. Neostigmine 26-37 butyrylcholinesterase Homo sapiens 60-75 14953258-0 1952 [Inhibition of cholinesterase by prostigmine]. Neostigmine 33-44 butyrylcholinesterase Homo sapiens 15-29 14926259-0 1951 [Aneurine and cholinesterase after inhibition by prostigmine]. Neostigmine 49-60 butyrylcholinesterase Homo sapiens 14-28 29317084-4 2018 Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine. Neostigmine 69-80 butyrylcholinesterase Homo sapiens 31-45 29317084-4 2018 Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine. Neostigmine 221-232 butyrylcholinesterase Homo sapiens 31-45 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Neostigmine 238-249 butyrylcholinesterase Homo sapiens 48-52 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Neostigmine 288-299 butyrylcholinesterase Homo sapiens 48-52 24032987-1 2013 BACKGROUND AND PURPOSE: Cholinesterase inhibitors such as neostigmine are used for acute colonic pseudo-obstruction, but cardio-bronchial side-effects limit use. Neostigmine 58-69 butyrylcholinesterase Homo sapiens 24-38 24357101-3 2014 Plasma samples were prepared on ice and neostigmine metilsulfate added as a cholinesterase inhibitor immediately after sample collection. Neostigmine 40-64 butyrylcholinesterase Homo sapiens 76-90 26840188-1 2016 BACKGROUND: Neostigmine, an acetyl cholinesterase inhibitor, stimulates colonic motor activity and may induce vagally mediated cardiovascular effects. Neostigmine 12-23 butyrylcholinesterase Homo sapiens 35-49 19806080-2 2009 In this study, we used the cholinesterase inhibitor, neostigmine, to explore the mechanism of the narcoleptic IgG-mediated disruption of enteric motor function in four patients with narcolepsy with cataplexy and to identify a pharmacological mimic of the Ab. Neostigmine 53-64 butyrylcholinesterase Homo sapiens 27-41